In addition, the PSA doubling time for the SFN group was 86% longer in comparison to the placebo group, all suggesting that SFN provides clinical efficacy in cancer prevention, specifically for prostate cancer [60]. This evidence concerns the gene KLK3 and Familial prostate cancer.